School-based online survey on chronic headache, migraine, and medication-overuse headache prevalence among children and adolescents in Japanese one city – Itoigawa Benizuwaigani study

Katsuki, Masahito; Matsumori, Yasuhiko; Kawahara, Junko; Yamagishi, Chinami; Koh, Akihito; Kawamura, Shin; Kashiwagi, Kenta; Kito, Tomohiro; Oguri, Masato; Mizuno, Shoji; Nakamura, Kentaro; Hayakawa, Katsushi; Ohta, Osamu; Kubota, Noa; Nakamura, Hina; Aoyama, Jun; Yamazaki, Isamu; Mizusawa, Satoshi; Ueki, Yasuhide; Ikeda, Takashi; Yamagishi, Fuminori

doi:10.1016/j.clineuro.2023.107610

Cited by 18 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Age and headache characteristics were also collected, and MOH diagnosis was made in the same way in the previous studies. 4,5,7…”

Section: Campaign Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Headache Education by E-learning Through Social Networking Services

Katsuki¹,

Nanri²,

Miyakoshi³

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction Headache is a common public health problem, but its burden could be avoided by raising headache awareness and the appropriate use of acute medication and prophylactic medication. Few reports on raising headache awareness in the general public have been reported, and there are no reports on headache awareness campaigns through social networking services (SNS), or social media, in Japan. We prospectively performed a headache awareness campaign from March 2022 through 2 SNS, targeting nurse and wind instrumental musicians, because they are with high headache prevalence. Methods Through the 2 SNS, the article and video were distributed, respectively. The article and video described the 6 important topics for the general public about headaches, which were described in the Clinical Practice Guideline for Headache Disorders 2021. Just after reading or watching them as e-learning, we performed online questionnaire sheets to investigate the awareness of the 6 topics through the 2 SNS. The awareness of the 6 topics before and after the campaign was evaluated. Results In the SNS nurse-senka, we obtained 1191 responses. Women comprised 94.4%, and the median (range) age was 45 (20 to 71) years old. Headache sufferers were 63.8%, but only 35.1% had consulted doctors. In the SNS Creatone, we got the response from 134 professional musicians, with 77.3% of women. The largest number of respondents were in their 20s (range 18-60 years old). Headache sufferers were 87.9%. Of them, 36.4% had consulted doctors, 24.2% were medication-overuse headache. The ratios of individuals who were aware of the 6 topics significantly increased from 15.2%-47.0% to 80.4-98.7% after the online questionnaire in both SNS (p < 0.001, all). Conclusions We conducted this headache awareness campaign through e-learning and an online survey via 2 SNS. The ratios of individuals who were aware of the 6 topics about headaches significantly increased 1 month after e-learning. Our results suggest that e-learning and online survey can improve headache awareness. The materials in this campaign can be installed into smartphone applications and further spread on SNS, leading to strong influence. With rapid digital transformations such as online telemedicine and artificial intelligence diagnosis, raising awareness will be more efficient and effective and should be important.

show abstract

“…Age and headache characteristics were also collected, and MOH diagnosis was made in the same way in the previous studies. 4,5,7…”

Section: Campaign Proceduresmentioning

confidence: 99%

“…3 Migraine prevalence is 0.9-9.5%. [4][5][6][7][8][9][10] The economic and social impacts of migraine on productivity are starting to be recognized. [11][12][13] Still, there was an unmet need for migraine care: 89.8% of respondents had never taken preventative medicine for headaches, and 36.5% had been hesitant to consult doctors.…”

Section: Introductionmentioning

confidence: 99%

Headache Education by E-learning Through Social Networking Services

Katsuki¹,

Nanri²,

Miyakoshi³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In Japan, migraine prevalence is 4.3-8.4% [2][3][4], and 29.8-74.2% of patients with migraine headaches report that it significantly impairs their daily activity [1]. Also, the migraine prevalence among adolescents aged 15 to 17 years old is 16.2% and those of medicationoveruse headache (MOH) is 1.5% in Japan [5]. Effective prophylactic treatment for adolescents with migraine is needed.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines

Katsuki¹,

Kashiwagi²,

Kawamura³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

IntroductionAdolescent migraines is a public health problem, and effective prophylactic treatment is needed. In Japan, three types of calcitonin gene-related peptide-related monoclonal antibodies (CGRP-mABs) are available. Galcanezumab, fremanezumab, and erenumab can be used for migraine prevention in ages 15 years or older, but reports on adolescent migraine treated with CGRP-mABs remain few. We described this study to report the real-world data of CGRP-mABs' efficacy for adolescents with migraines aged from 15 to 17 years old. MethodsWe retrospectively investigated ten adolescent migraine patients aged from 15 to 17 years old treated with CGRP-mABs. Headache impact test-6 (HIT-6), monthly headache days (MHD), and monthly acute medication intake days (AMD) before and three months after CGRP-mABs treatment were evaluated. ResultsSix females and four males were included. Seven had episodic migraines (EM), three had EM and tensiontype headaches, one had chronic migraines (CM), and one had CM and medication-overuse headaches. As chief obstacles to life due to headaches, five reported them as detrimental to study, one reported them as detrimental to playing sports, and four reported missing school. The median HIT-6 was 63 (46-68) and 44 (36-65) before and three months after treatment, respectively. Median of MHD was 5.5 (1-29) and 1.5 (1-30), respectively, and the median of AMD was 5.5 (1-30) and 1 (0-30), respectively. A significant reduction of HIT-6 was observed at three months (p=0.008). Six (60%) of the ten patients experienced therapeutic effectiveness. Patients with missing school as the chief obstacle to life due to headaches seemed ineffective compared to those with other obstacles (p=0.048). There were no side effects of CGRP-mABs. ConclusionWe herein described the ten adolescent migraine patients treated with CGRP-mABs. HIT-6 score significantly decreased at three months, and six of the ten patients experienced therapeutic effectiveness measured by HIT-6. Now several trials have been ongoing to test the efficacy of CGRP-mABs for adolescents. Urgent evidence accumulation is needed about CGRP-mABs for adolescents.

show abstract

“…Migraine is a widespread public health problem [1]. In Japan, migraine prevalence is 4.3-8.4% [2][3][4][5], and 29.8-74.2% of patients with migraine headaches report that it significantly impairs their daily activity [1]. Also, the migraine prevalence among elderly aged over 64 years old is 0.9%, and those of medicationoveruse headache (MOH) is 0.7% in Japan [6].…”

Section: Introductionmentioning

confidence: 99%

Fremanezumab for Migraine Prevention in Japanese Elderly Aged Over 70 Years Old

Katsuki¹,

Kashiwagi²,

Kawamura³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundElderly migraine is a public health problem with prolonged life expectancy, and effective prophylactic treatment is needed. There were no reports on fremanezumab for the elderly. We described the real-world data of fremanezumab, calcitonin gene-related peptide-related monoclonal antibody (CGRP-mAB), for migraine in elderly over 70 years old. MethodsWe retrospectively investigated six elderly migraine patients over 70 years old treated with fremanezumab. Headache impact test-6 (HIT-6), monthly headache days (MHD), and monthly acute medication intake days (AMD) before one and three months after starting fremanezumab treatment were evaluated. ResultsThree women and three men (median age 78; range: 71-99) were included. One was chronic migraine (CM), three were CM and medication-overuse headache, and two were episodic migraine and tension-type headache. All six patients received monthly fremanezumab. The median MHD before, during one, and three months after treatment were 30 (4-30), 30 (4-30), and 29 (15-30, n=4). Those of AMD were 17 (0-30), 9.5 (0-30), and 1 (0-28). Those about HIT-6 were 64 (56-72), 59.5 (52-70), and 55. 5 (48-64). Two (33.3%) of the six patients experienced therapeutic effectiveness. There were no side effects. ConclusionWe described the six elderly migraine patients aged over 70 years old treated with fremanezumab. Two (33.3%) of the six patients experienced therapeutic effectiveness. This is the first report of fremanezumab for elderly migraine patients aged over 70 years old. Further evidence accumulation is needed about CGRP-mABs for the elderly.

show abstract

School-based online survey on chronic headache, migraine, and medication-overuse headache prevalence among children and adolescents in Japanese one city – Itoigawa Benizuwaigani study

Cited by 18 publications

References 35 publications

Headache Education by E-learning Through Social Networking Services

Headache Education by E-learning Through Social Networking Services

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines

Fremanezumab for Migraine Prevention in Japanese Elderly Aged Over 70 Years Old

Contact Info

Product

Resources

About